46 results on '"Lichtenstein, Gary R"'
Search Results
2. Hospitalization Outcomes for Inflammatory Bowel Disease in Teaching vs Nonteaching Hospitals
3. A User-Friendly Prediction Tool to Identify Colectomy Risk in Patients With Ulcerative Colitis
4. Mimics of Inflammatory Bowel Disease
5. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program
6. Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
7. Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization
8. Inflammatory Bowel Disease: Predictors and Causes of Early and Late Hospital Readmissions
9. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program.
10. The Impact of Introducing Patient-Reported Inflammatory Bowel Disease Symptoms via Electronic Survey on Clinic Visit Length, Patient and Provider Satisfaction, and the Environment Microbiome
11. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program
12. Preadmission Cannabis Use Is Positively Correlated With Inpatient Opioid Dose Exposure in Hospitalized Patients With Inflammatory Bowel Diseases
13. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data.
14. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
15. The Impact of Introducing Patient-Reported Inflammatory Bowel Disease Symptoms via Electronic Survey on Clinic Visit Length, Patient and Provider Satisfaction, and the Environment Microbiome.
16. Preadmission Cannabis Use Is Positively Correlated With Inpatient Opioid Dose Exposure in Hospitalized Patients With Inflammatory Bowel Diseases.
17. P014 AVERAGE ANNUAL HEALTHCARE COSTS FOR PEDIATRIC AND ADULT PATIENTS WITH CROHN’S DISEASE OR ULCERATIVE COLITIS
18. P148 LACK OF INFLUENCE OF ELDERLY AGE AND GENDER ON THE SAFETY PROFILE OF BUDESONIDE EXTENDED-RELEASE TABLETS FOR ULCERATIVE COLITIS: A POOLED ANALYSIS OF TWO RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIALS
19. Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization
20. Inflammatory Bowel Disease
21. How to Assess and Document Endoscopies in IBD Patients by Including Standard Scoring Systems
22. Measurement of Inflammatory Bowel Disease Symptoms
23. Long-term Safety and Tolerability of Once-daily Mesalamine Granules in the Maintenance of Remission of Ulcerative Colitis
24. Impact of JC Virus Antibody Testing in Patients with Crohnʼs Disease with Loss of Response to Infliximab
25. Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension Studies
26. Long-term remission with certolizumab pegol in Crohnʼs disease: Efficacy over 5 years in patients with no prior anti-TNF agent exposure (precise 3 study)
27. Combination of genetic and quantitative serological immune markers are associated with complicated Crohnʼs disease behavior
28. Crohnʼs disease patients with persistently elevated CRP plasma concentration have higher rates of remission with certolizumab pegol 400 mg every 2 weeks vs every 4 weeks
29. Sustained remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohnʼs disease exacerbation who were naïve to anti-TNF treatment: 5-year results from PRECiSE 4
30. Importance of mucosal healing in ulcerative colitis
31. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate Ulcerative Colitis
32. Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis
33. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: A clinical review and update
34. Safety of biologic therapy
35. Natalizumab, Anti-Il-12, Alicaforsen, Plasmapheresis, Protease Inhibitors, Phosphodiesterase Inhibitors (Present)
36. Prevention and treatment of osteoporosis in inflammatory bowel disease
37. Optimizing Therapy in Patients with Pancolitis
38. Methods to Avoid Infections in Patients with Inflammatory Bowel Disease
39. Maintaining Remissions Across the Lifespan
40. Crohn’s Is Not a 6-Week Disease
41. Long-Term Treatment of Crohn’s Disease
42. Infliximab Improves Quality of Life in Patients with Crohn's Disease
43. Is Infliximab Effective for Induction of Remission in Patients with Ulcerative Colitis?
44. Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease
45. Increased expression of interleukin-8 mRNA in ulcerative colitis and Crohn's disease mucosa and epithelial cells
46. Commentary. Is infliximab effective for induction of remission in patients with ulcerative colitis?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.